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dates for RCTs.
4. Standardization of International Policy Committee in-
cluding studies to determine the optimal characteristics
of the ideal device and electronic methods to streamline
and facilitate compliance.
5. Using the electronic medical record software to collect
risk data, suggest care pathways, and track long-term
outcomes and correlate them with risk score and pro-
phylaxis regime.
THE EFFECTIVENESS OF DEEP VEIN
THROMBOSIS PREVENTION
—Mark H. Meissner, MD, Seattle, Wash
Venous thromboembolism (VTE) is the second most
common complication among hospitalized patients and the
most common preventable cause of hospital death. Current
guidelines suggest that all hospitals have an active written
strategy for the prevention of VTE.1 Although there con-
tinues to be debate regarding individual vs group-specific
thromboprophylaxis models, the current American College
of Chest Physicians consensus guidelines support group-
specific thromboprophylaxis (Table). This is based on ob-
servations that the principal determinant of thromboem-
bolic risk is the indication for hospitalization; virtually all
randomized clinical trials have been based upon group risk
assignment; and complicated individual risk assessment
models may decrease physician compliance.1
The vast majority of thromboprophylaxis trials have
used venographically detected deep venous thrombosis
(DVT) as a surrogate marker for the patient-important
endpoints of symptomatic DVT, symptomatic pulmonary
embolism (PE), and fatal PE. Pharmacological prophylaxis
reduces the risk of asymptomatic DVT and symptomatic
Table. Group prophylaxis strategies adapted from Geerts
et al.1
Thromboembolic risk
DVT risk without
prophylaxis
Recommended
prophylaxis
Low
Minor surgery in mobile
patients
10% Early ambulation
Fully mobile medical patients
Moderatea LMWH or
Most general, gynecologic,
and urology patients
10% to 40% LDUH bid/tid
or
Medical patients, ill or non-
mobile
Fondaparinux
Higha
Hip/knee arthroplasty, hip
fracture
LMWH or
Major trauma 40% to 80% Fondaparinux or
Spinal cord injury VKA
bid, Twice a day; DVT, deep venous thrombosis; LDUH, low dose unfrac-
tionate heparin; LMWH, low molecular weight heparin; tid, three times a
day; VKA, vitamin K antagonist.
aConsider mechanical prophylaxis in patients with high bleeding risk; switch
to anticoagulant prophylaxis when bleeding risk decreases.VTE by 60% to 70% in general surgery patients (unfraction-
ated heparin [UFH], low molecular weight heparin
[LMWH]),1 by 70% to 76% in orthopedic patients
(LMWH, warfarin),2 and by 45% in medical patients who
are acutely ill (UFH, LMWH).3 Thromboprophylaxis with
UFH, LMWH, or fondaparinux is a strong recommenda-
tion for moderate and high-risk patients of general surgery
(grade 1A) and combined pharmacological and mechanical
prophylaxis should be considered in very high-risk patients
(grade 1C). Prophylaxis with LMWH, fondaparinux, or
adjusted dose vitamin K antagonist similarly receives a
strong recommendation (grade 1A) among patients under-
going hip or knee arthroplasty.
Despite the fact that few clinical trials are powered to
demonstrate a reduction in the patient, important out-
comes of symptomatic VTE or death, there is a strong
relationship between systematically detected DVT and
these clinically relevant acute outcomes. In a meta-analysis
of eight studies comparing LMWH prophylaxis with pla-
cebo in patients who received general surgery, LMWH
heparin was not only associated with a 72% relative risk
reduction in the primary endpoint of imaging-detected
DVT, but with similar 71% and 75% relative risk reductions
in the incidence of symptomatic VTE and PE.4 Significant
decreases in fatal PE among patients randomized to UFH
have also been demonstrated.5 Meta-analysis of 52 hip
arthroplasty trials including 10,292 patients also demon-
strated a significant reduction in symptomatic PE, although
such trials would need to include over 100,000 patients to
demonstrate a 50% reduction in fatal pulmonary embo-
lism.2 In contrast, although prophylaxis in patients who are
acutely ill medically decreases the risk of imaging-detected
DVT, a reduction in symptomatic DVT3 and pulmonary
embolism6 has not clearly been demonstrated.
Despite the importance of postoperative VTE, the as-
sociated mortality is only 0.1% to 1.0% and the long-term
consequences of the postthrombotic syndrome (PTS)
could in fact be a greater socioeconomic problem.7 If
asymptomatic postoperative DVT leads to PTS, effective
thromboprophylaxis would be an important means of re-
ducing the incidence of severe chronic venous disease. The
well-recognized association between symptomatic DVT
and PTS favors such a relationship. However, several
largely theoretical factors suggest that postoperative DVT
may be associated with a lower risk of PTS than that
developing in other settings. The long-term importance of
small, asymptomatic, nonocclusive and largely distal
thrombi can certainly be questioned. Although some8 have
found no relationship between thrombus location and the
development of PTS, others7,9 have demonstrated PTS to
occur 4 to 6 times more often among those with proximal
in comparison to distal thrombi. Furthermore, symptom-
atic postoperative thrombi have been associated with a
more rapid rate of recanalization and significantly lower risk
of recurrence,10 well-recognized factors in the develop-
ment of the PTS.
Unfortunately, PTS has not been included as a primary
outcome measure in any randomized trials evaluating VTE
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between effective thromboprophylaxis and PTS is difficult
to infer from the available data. Most data, which is often
conflicting, comes from the joint arthroplasty literature.
Most authors report PTS in 5% to 18% of patients after joint
arthroplasty, although this incidence is not clearly related to
the presence of either symptomatic or asymptomatic DVT
(Fig). Although the frequency of thromboprophylaxis is
difficult to discern, Siragusa et al9 reported PTS in 23.9% of
patients with asymptomatic DVT in comparison to 3.8% of
controls. Even with LMWH prophylaxis, Schindler et al7
reported the development of PTS in 16.7% of patients with
DVT, although those with distal DVT were treated only
with aspirin. However, several authors have reported a
similarly low incidence of PTS among those with and
without DVT. Using a definition that included clinical
symptoms and objective evidence of reflux, Ginsberg et al8
found no difference in the incidence of PTS among those
with asymptomatic proximal (4.0%) or distal (6.1%) DVT
and those without DVT (4.3%) after hip or knee arthro-
plasty. McAndrew et al11 also demonstrated a similar inci-
dence of postthrombotic signs and symptoms among those
with (6%) and without (8%) DVT detected by ultrasound
scan. Others have also reported very low rates of PTS after
postarthroplasty DVT.12,13
Unfortunately, the currently available data regarding
the relationship between systematically detected asymp-
tomatic DVT and PTS has many shortcomings. Effective
thromboprophylaxis, as used in at least some of these
studies, may have reduced the size and extent of thrombus,
and accordingly, the incidence of PTS. Lack of effective
prophylaxis could theoretically lead to a higher incidence of
PTS. The duration of thromboprophylaxis in most studies
was also quite short. Among orthopedic patients given
prophylaxis for 7 to 10 days, two-thirds of symptomatic,
nonfatal thromboembolic events and almost half of fatal
Fig. Incidence of postthrombotic syndrome (PTS) after joint ar-
throplasty. DVT, Deep vein thrombosis.PEs occur after prophylaxis has been withdrawn.14 It iscertainly possible that the equivalent incidence of PTS in
patients without early venographic DVT is due to subclin-
ical DVT developing after venographic screening. Finally,
most patients with asymptomatic postoperative DVT are
treated with an early course of anticoagulation, potentially
reducing the incidence of PTS. It is certainly possible that
patients with undetected DVT would have a higher inci-
dence of PTS.
The data regarding the relationship between asymp-
tomatic DVT and PTS are of poor quality and no trials
comparing the incidence of PTS among patients treated
with an effective thromboprophylactic regimen in compar-
ison to placebo will ever be done. However, the value of
thromboprophylaxis in reducing the incidence of the post-
thrombotic syndrome may be an irrelevant question. Effec-
tive thromboprophylaxis is effective in reducing the inci-
dence of symptomatic VTE and should be provided to all
at-risk patients.1 Efforts should focus on insuring that all
at-risk patients receive prophylaxis, irrespective of its effect
on prevention of PTS.
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CRITICAL ISSUES IN ULCER PREVENTION IN
POSTTHROMBOTIC DISEASE
—Seshadri Raju, MD, Flowood, Miss
Postthrombotic syndrome (PTS) is a major source of
venous ulcers accounting for an estimated 	50% as caus-
ative etiology. A total of 1% to 7% of patients with PTS are
estimated to develop an ulcer in 5 to 10 years, but the true
incidence is not known as recurrent thrombosis is a major
factor in PTS development (grade 1).1 Recurrent throm-
boses are known to occur years and even decades later2,3
making accurate estimation of true PTS and ulcer incidence
impossible as a practical matter.
For purposes of this article, we will assume that any
reduction in overall incidence of PTS will also result in ulcer
prevention as ulcer-specific data is nonexistent.We examine
below known and potential avenues of preventing or con-
trolling PTS symptoms.
ANTICOAGULATION
Prevention of recurrent thrombosis will likely reduce
eventual ulcer incidence.4 This rests on proper use of
anticoagulation in vulnerable subsets to prevent recurrent
thromboses; permanent anticoagulation may be indicated.
Predisposing factors for recurrent thrombosis includes un-
provoked thromboembolism (grade 1),1,5 incomplete res-
olution of initial thrombus (grade 1),6,7 chronic venous
disease (grade 1), thrombophilia,1,2 obesity, female gen-
der, and age.2,8 There is some dispute regarding the rele-
vancy of the last four factors in recurrent thrombosis or
development of PTS.9,10 Initial severity of symptoms is a
predictor for development of PTS (grade 3).8,11 A number
of newer anticoagulants that are easier to administer, mon-
itor, and regulate are likely to come on stream in the near
future. This will likely make it easier to prevent recurrent
thromboses. Speedy approval of effective drugs should be
encouraged. Several such agents have been shown to be
effective in Europe but face delay and hurdles for United
States approval.
COMPRESSION
Compression stockings and assist devices12 have been
shown to have prophylactic value in several studies, some
extending 5 to 7 years (grade 1B).1,13-15 A few contradic-
tory results have been reported16,17 probably due to low
power, short follow-up, or variability of compression use
including noncompliance. Class I or II stockings are re-
quired for effective prophylaxis of PTS after venous throm-
bosis had occurred, grade 3 evidence18 and stockings fre-
quently used as prophylaxis against deep vein thrombosis
(eg, thrombo embolic deterrent hose) do not provide
adequate compression. A high percentage of patients dis-charged with compression stockings do not use them lat-
er.19,20
Current practice patterns allow considerable room for
improvement in proper prescription, usage, and compli-
ance monitoring.
LYSIS
Lytics, via systemic or catheter route, resolve throm-
bus,21 and improve long-term patency22 (grade 2). Cathe-
ter lysis has been shown to preserve valve function and
reduce reflux near term23-26 and improve quality of life at 2
years (grade 3).27 These surrogate endpoints suggest that
PTS incidence may be improved long-term as well. Defin-
itive studies are pending.
Pharmaco-mechanical thrombectomy is currently be-
ing evaluated for removal of thrombus and preliminary
results have appeared in print.28-30
PATHOLOGY
There is broad agreement that the pathology of PTS is
combined obstruction and reflux even though available
evidence is only grade 2.31-33 Respective role of reflux or
obstruction is undetermined. A large body of work spread
over the past century has clearly established the importance
of reflux in PTS. Recent grade 3 evidence has ignited
interest in the clinical importance of obstruction.34,35 Sub-
stantial clinical relief, including healing of ulceration, was
reported in a large series of 528 limbs when the obstructive
component was corrected and the reflux (severe in 59%
with 42% being axial) was left uncorrected.36 Conflicting
reports have also appeared regarding the relative impor-
tance of affected vein segments in these two pathologies
(obstruction and reflux). Regarding obstruction, attention
has focused on the proximal vein segments (iliac-femoral)
and the distal segments (popliteal-tibial); femoral vein oc-
clusion seems to be well-compensated with good collater-
alization from the deep femoral vein (grade 3).31,37 Grade
2 and 3 evidence has been presented in support of the
importance of proximal vein obstruction either alone or in
concert with distal segment in the development of
PTS.35,38-42 However, obstruction of distal vein segments
has been related to the development of PTS also (grade 3
evidence).43-46 Similarly conflicting (grade 3) data has ap-
peared regarding the relative roles of proximal or distal
segment reflux47,48 including the concept of ‘gate keeper’
valve44,49-52 in the genesis of PTS symptoms.
We have inadequate understanding of the interaction
between postthrombotic obstruction and reflux and their
relative importance. Thrombus resolution seems to spare
valve function53 in some instances and reflux seems to
occur in previously thrombosed33 and unthrombosed valve
segments as well.52,54,55 The mechanism of postthrom-
botic valve reflux seems more complex than initially ap-
pears.52,55,56 Basic science work in this area is sorely
needed. Techniques to quantify obstruction and reflux are
necessary to understand the pathology and target treat-
ment. It should be noted that current data regarding spon-
taneous thrombus resolution pertains only to morphologic
